About
Larry Tremaine, PhD is a drug-metabolism and pharmacokinetics scientist who serves as Chief Scientific Officer at Dialectic Therapeutics. Dialectic says he spent more than three decades at Pfizer, where he led DMPK laboratory groups and contributed to approved drugs including Zoloft, Geodon, Chantix, Eliquis, and Xeljanz. Equilar also lists him as an advisor to Clear Creek Bio.
Areas of interest
biotechoncologydrug metabolismpharmacokineticspreclinical DMPKCNS drug discoverybrain penetration research